FT is investigating potential claims on behalf of shareholders of IMS Health (NYSE:RX) arising from the Company’s announcement of its intent to be acquired by investment funds managed by TPG Capital  and the CPP Investment Board. 

Under the terms of the proposed agreement, IMS shareholders will receive $22 cash for each share of IMS common stock they own. The transaction has a total value of $5.2 billion, including the assumption of debt.

The investigation is focused on the potential unfairness of the price to IMS shareholders and the process by which the IMS Board of Directors considered and approved the transaction. As of September 30, 2009, the Company had over $300 million in cash – a position that may not be adequately valued in this proposed agreement.

If you are interested in discussing your rights as an IMS shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it